+A -A

Tabela:
Comparative View:

3Q18 Create chart
Net sales revenues 1,512,525
Change in Fair Value of Biological Assets 49,083
Cost of Goods Sold -836,479
Depreciation / Amortization / exhaustion -173,919
Exhaustion of biological assets -123,839
Gross Profit 427,371
Selling Expenses -193,802
General and Administrative Expenses -48,676
Management Compensation -4,152
Other Operating Compensation 412,434
Equity income from subsidiaries 0
Operating Profit before Financial Income and Equity 593,175
Financial Income 47,097
Financial Expenses -74,579
Income Before Income Tax and Social Contribution 565,693
Income and social contribution taxes - current -211,627
Income Tax and Social Contribution - Deferred 22,282
Effect profit from discontinued operation 0
Net Income 376,348
Recurring Net Income 61,566
Recurring EBITDA 209,566
EBITDA Margin 16.4 %

* Because of the date of the merger between Duratex and Satipel, 31.08.09, include data only from the "old" Duratex

**from 1Q 12 the data does not include discontinued operation, Deca Piazza